You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

Claims for Patent: 6,022,539

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,022,539

Title:	Amelioration of peyronie\'s disease
Abstract:	A method of treating an individual suffering from Peyronie\'s disease. Collagenase is injected into a fibrous Peyronie\'s plaque in the penis of the individual suffering from the disease. The penis immediately after injection, is immobilized and maintained immobile for several hours. The collagenase is in a pharmaceutically acceptable carrier in a concentration of about 20,000 to about 40,000 ABC units per ml., and the amount and concentration of the collagenase is effective to soften and/or rupture the plaque whereby the erectile deviation caused by the plaque is ameliorated
Inventor(s):	Wegman; Thomas L. (North Merrick, NY)
Assignee:	Advance Biofactures of Curacao (Curacao, AN)
Application Number:	09/325,224
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,022,539
Patent Claims:	1. A method of treating an individual suffering from Peyronie's disease which comprises injecting collagenase into a fibrous Peyronie's plaque in the penis of the individual suffering from the disease, immobilizing the penis immediately after injection, and maintaining the penis immobile for several hours, the collagenase being in a pharmaceutically acceptable carrier in a concentration of about 20,000 to about 40,000 ABC units per ml., and the amount and concentration of the collagenase being effective to soften and/or rupture the plaque whereby the erectile deviation caused by the plaque is ameliorated. 2. A method according to claim 1 wherein a total amount of at least about 20,000 ABC units of collagenase are applied in one or more injections. 3. A method according to claim 1 wherein the maximum cumulative total dosage does not exceed about 60,000 ABC units. 4. A method according to claim 1 wherein the period of immobility is from about 4 to about 12 hours. 5. A method according to claim 1 wherein that method is repeated after about 3 months. 6. A method according to claim 1 wherein the collagenase is in an aqueous carrier. 7. A method of treating an individual suffering from Peyronie's disease which comprises injecting into a fibrous Peyronie's plaque in the penis of the individual suffering from the disease a series of at least two injections of at least about 10,000 ABC units each of collagenase at least one day apart to provide a total amount of at least about 20,000 ABC units, the amount and concentration of the collagenase being effective to soften and/or rupture the plaque whereby the penile flexure caused by the plaque is ameliorated. 8. A method according to claim 7 wherein each injection is of about 10,000 to about 20,000 ABC units. 9. A method according to claim 7 wherein the collagenase is supplied in a pharmaceutically acceptable carrier in a concentration of about 20,000 to about 40,000 ABC units per ml. 10. A method according to claim 7 wherein the maximum cumulative dosage does not exceed about 60,000 ABC units. 11. A method according to claim 7 wherein a series of at least 3 injections is made during a period of not over ten days. 12. A method according to claim 7 wherein a series of approximately weekly injections of about 10,000 to about 20,000 ABC units each is made up to a maximum cumulative total dosage not to exceed about 60,000 ABC units. 13. A method according to claim 7 wherein another series of injections is made after 3 months. 14. A method according to claim 7 wherein the collagenase is in an aqueous carrier. 15. A method according to any one of claims 1-6 further comprising after the step of immobilization, then physically rupturing the plaque by manipulation. 16. A method according to any one of claims 7-14 further comprising the step of physically rupturing the plaque by manipulation.

Details for Patent 6,022,539

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	June 04, 1965	⤷ Sign Up	2039-03-29
Auxilium Pharmaceuticals, Inc.	XIAFLEX	collagenase clostridium histolyticum	For Injection	125338	February 02, 2010	⤷ Sign Up	2039-03-29
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 6,022,539

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Australia	3532900	⤷ Sign Up
Canada	2308842	⤷ Sign Up
Germany	10027521	⤷ Sign Up
Denmark	177177	⤷ Sign Up
Denmark	200000792	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.